Tricuspid regurgitation pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Tricuspid regurgitation}}
{{Tricuspid regurgitation}}
{{CMG}}; {{AE}} {{Rim}}
{{CMG}} {{AE}} {{Rim}} {{FB}}


==Overview==
==Overview==

Revision as of 15:22, 30 March 2017

Tricuspid Regurgitation Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tricuspid Regurgitation from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Stages

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography

Chest X Ray

Electrocardiogram

Cardiac Stress Test

Cardiac MRI

Cardiac Catheterization

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Tricuspid regurgitation pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tricuspid regurgitation pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onTricuspid regurgitation pathophysiology

CDC on Tricuspid regurgitation pathophysiology

Tricuspid regurgitation pathophysiology in the news

Blogs on Tricuspid regurgitation pathophysiology

Directions to Hospitals Treating Tricuspid regurgitation

Risk calculators and risk factors for Tricuspid regurgitation pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2] Fatimo Biobaku M.B.B.S [3]

Overview

Tricuspid regurgitation (TR) results in a retrograde flow of blood into the right atrium due to the incompetent tricuspid valve. The pathophysiology of TR depends on whether TR is primary or secondary. Primary TR results from an organic abnormality in one or more parts of the tricuspid valve, such as the leaflets, chordae tendineae, or papillary muscles.[1] Secondary TR commonly results from hemodynamic and structural changes in the right ventricle and tricuspid valve apparatus secondary to left-sided heart pathology and/or pulmonary hypertension.[2] Tricuspid annular dilation is the most important factor in the pathophysiology of secondary TR. In addition, tethering of the leaflets and inadequate leaflet coaptation also contribute to secondary TR.[3]

Pathophysiology

The Tricuspid Valve Apparatus

The tricuspid valve apparatus includes the following structures:[3]

Primary Tricuspid Regurgitation

Primary TR results from an organic abnormality in one or more parts of the tricuspid valve. Conditions that might contribute to the primary distortion of the tricuspid valve include rheumatic heart disease and congenital, iatrogenic, or infectious etiologies.[1]

Secondary Tricuspid Regurgitation

More than 80% of the cases of TR seen in clinical practice is secondary(functional) in nature and related to tricuspid annular dilatation and leaflet tethering in the setting of right ventricular remodelling caused by pressure or volume overload (or both), myocardial infarction, or trauma.[2] The underlying pathophysiology of secondary TR involves the following changes:[3]

  • Left heart failure and/or pulmonary hypertension causes dilation of the right ventricle and subsequent tricuspid annular dilation.
  • The tricuspid annular dilatation leads to a disruption of the coordinated function of the papillary muscle, tricuspid leaflets and the tricuspid annulus, causing tethering of the leaflets.
  • When secondary TR is present, it causes further progressive right ventricular remodelling which distort normal leaflet coaptation.

In summary, tricuspid annular dilation is the most important factor in the pathophysiology of secondary TR, though tethering of the leaflets and inadequate leaflet coaptation also contribute to secondary TR.[3]

References

  1. 1.0 1.1 Rogers JH, Bolling SF (2009). "The tricuspid valve: current perspective and evolving management of tricuspid regurgitation". Circulation. 119 (20): 2718–25. doi:10.1161/CIRCULATIONAHA.108.842773. PMID 19470900.
  2. 2.0 2.1 Rodés-Cabau J, Taramasso M, O'Gara PT (2016). "Diagnosis and treatment of tricuspid valve disease: current and future perspectives". Lancet. 388 (10058): 2431–2442. doi:10.1016/S0140-6736(16)00740-6. PMID 27048553 PMID: 27048553 Check |pmid= value (help).
  3. 3.0 3.1 3.2 3.3 Taramasso M, Vanermen H, Maisano F, Guidotti A, La Canna G, Alfieri O (2012). "The growing clinical importance of secondary tricuspid regurgitation". J Am Coll Cardiol. 59 (8): 703–10. doi:10.1016/j.jacc.2011.09.069. PMID 22340261.

Template:WH Template:WS